Advanced search
Publication Cover
Journal of Medical Economics Volume 22, 2019 - Issue 1
Submit an article Journal homepage
1,500
Views
3
CrossRef citations to date
0
Altmetric
Oncology

Cost-effectiveness of pembrolizumab versus brentuximab vedotin for patients with relapsed or refractory classical Hodgkin’s lymphoma: a United States payer perspective

Samuel LargePAREXEL International, London, UK; View further author information
,
Robert HettlePAREXEL International, London, UK; View further author information
,
Arun BalakumaranMerck & Co., Inc., Kenilworth, NJ, USAView further author information
,
Elise WuMerck & Co., Inc., Kenilworth, NJ, USAView further author information
&
Rebekah H. BorseMerck & Co., Inc., Kenilworth, NJ, USACorrespondence[email protected]
View further author information
Pages 16-25 | Received 08 Mar 2018, Accepted 02 Oct 2018, Published online: 13 Nov 2018

Citations (3)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Monika Raut, Gautamjeet Singh, Immaculata Hiscock, Sheetal Sharma & Nameeta Pilkhwal. (2022) A systematic literature review of the epidemiology, quality of life, and economic burden, including disease pathways and treatment patterns of relapsed/refractory classical Hodgkin lymphoma. Expert Review of Hematology 15:7, pages 607-617.
Read now
Ziyan Chen, Yue Cheng, David DeRemer & Vakaramoko Diaby. (2021) Cost-effectiveness and drug wastage of immunotherapeutic agents for hematologic malignancies: a systematic review. Expert Review of Pharmacoeconomics & Outcomes Research 21:5, pages 923-941.
Read now

Articles from other publishers (1)

Jalal Arabloo, Samad Azari, Hasan Abolghasem Gorji, Aziz Rezapour, Vahid Alipour & ‬Seyed Jafar Ehsanzadeh. (2023) Cost-effectiveness of brentuximab vedotin in Hodgkin lymphoma: a systematic review. European Journal of Clinical Pharmacology 79:11, pages 1443-1452.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.